Known targets — ChEMBL curated mechanism
ACEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2BTKCACNA1CCACNA1DCACNA1FCACNA1SCCR5CPT1BCPT2DPP4DRD1DRD2EGFRERBB2ERBB4HRH1HRH3HTR1AHTR2AHTR2BHTR2CHTR4JAK1JAK2JAK3MPLMTORPPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PPARGSLC6A2SLC6A3SLC6A4SMOTYK2pol
The experimentally established mechanism targets of Butaperazine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 known ✓ | P35367 | 8/20 | 0.60 |
| ▸ | HTR1A known ✓ | P08908 | 6/20 | 0.60 |
| ▸ | DRD2 known ✓ | P14416 | 6/20 | 0.60 |
| ▸ | ADRA2C known ✓ | P18825 | 6/20 | 0.60 |
| ▸ | SLC6A2 known ✓ | P23975 | 6/20 | 0.60 |
| ▸ | HTR2A known ✓ | P28223 | 6/20 | 0.60 |
| ▸ | SLC6A4 known ✓ | P31645 | 6/20 | 0.60 |
| ▸ | ADRA1A known ✓ | P35348 | 6/20 | 0.60 |
| ▸ | SLC6A3 known ✓ | Q01959 | 6/20 | 0.60 |
| ▸ | ADRA2A known ✓ | P08913 | 5/20 | 0.60 |
| ▸ | DRD1 known ✓ | P21728 | 5/20 | 0.60 |
| ▸ | ADRA2B known ✓ | P18089 | 5/20 | 0.60 |
| ▸ | HTR2B known ✓ | P41595 | 4/20 | 0.60 |
| ▸ | HRH3 known ✓ | Q9Y5N1 | 4/20 | 0.60 |
| ▸ | HTR2C known ✓ | P28335 | 4/20 | 0.57 |
| ▸ | MTOR known ✓ | P42345 | 2/20 | 0.57 |
| ▸ | ADRB1 known ✓ | P08588 | 1/20 | 0.57 |
| ▸ | ADRA1D known ✓ | P25100 | 1/20 | 0.57 |
| ▸ | ADRB2 known ✓ | P07550 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 6/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Butaperazine SCHEMBL120744 | 1.00 | LMNA (0.72) | LMNAMAPTMAPK1SMN1; SMN2NPSR1 | |
| Butaperazine SCHEMBL28086241 | 0.94 | HRH1 (0.67) | LMNAMAPTMAPK1SMN1; SMN2NPSR1 | |
| Butaperazine SCHEMBL119995 | 0.94 | HRH1 (0.67) | LMNAMAPTMAPK1SMN1; SMN2NPSR1 | |
| Butaperazine SCHEMBL31153317 | 0.94 | HRH1 (0.67) | LMNAMAPTMAPK1SMN1; SMN2NPSR1 | |
| Butaperazine SCHEMBL29710903 | 0.94 | HRH1 (0.67) | LMNAMAPTMAPK1SMN1; SMN2NPSR1 | |
| Perazine SCHEMBL220704 | 0.86 | MAPT (0.82) | LMNAMAPTMAPK1SMN1; SMN2NPSR1 | |
| Perazine SCHEMBL220703 | 0.86 | MAPT (0.82) | LMNAMAPTMAPK1SMN1; SMN2NPSR1 | |
| Carphenazine SCHEMBL120590 | 0.86 | HRH1 (0.72) | LMNAMAPTMAPK1SMN1; SMN2NPSR1 | |
| Thioproperazine SCHEMBL13723252 | 0.85 | DRD3 (0.79) | LMNAMAPTMAPK1SMN1; SMN2NPSR1 | |
| Prochlorperazine SCHEMBL5494383 | 0.84 | LMNA (1.00) | LMNAMAPTMAPK1SMN1; SMN2NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 169 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1044023-B1 | A COVALENT CONJUGATE OF CLOZAPINE WITH A FATTY ACID AND ITS USE FOR TREATING SCHIZOPHRENIA | LUITPOLD PHARM INC (US) | 2005-05-25 | — | — | EP | claimed |
| US-6197764-B1 | COMPLEX WITH FATTY ACID; THERAPY FOR PSYCHOLOGICAL DISORDERS | PROTARGA, INC. | 2001-03-06 | — | — | US | claimed |
| EP-1044023-A1 | A COVALENT CONJUGATE OF CLOZAPINE WITH A FATTY ACID AND ITS USE FOR TREATING SCHIZOPHRENIA | Protarga Inc. (US) | 2000-10-18 | — | — | EP | claimed |
| US-5955459-A | Fatty acid-antipsychotic compositions and uses thereof | NEUROMEDICA, INC. (US) | 1999-09-21 | — | — | US | claimed |
| WO-1999026661-A1 | A COVALENT CONJUGATE OF CLOZAPINE WITH A FATTY ACID AND ITS USE FOR TREATING SCHIZOPHRENIA | PROTARGA INC. (US) | 1999-06-03 | — | — | WO | claimed |
| EP-0180364-B1 | PHARMACEUTICAL COMPOSITIONS CONTAINING PHENOTHIAZINES | RECKITT AND COLMAN PRODUCTS LIMITED (GB) | 1990-03-07 | — | — | EP | claimed |
| EP-0180364-A2 | Pharmaceutical compositions containing phenothiazines | RECKITT AND COLMAN PRODUCTS LIMITED (GB) | 1986-05-07 | — | — | EP | claimed |
| EP-3749325-B1 | DREADD ACTUATORS | US HEALTH (US) | 2026-04-08 | — | — | EP | disclosed |
| US-20240247313-A1 | SEROTONIN TRANSPORTER GENE AND TREATMENT OF OPIOID-RELATED DISORDERS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2024-07-25 | — | — | US | disclosed |
| US-11905562-B2 | Serotonin transporter gene and treatment of opioid-related disorders | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2024-02-20 | — | — | US | disclosed |
| US-11739063-B2 | DREADD actuators | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2023-08-29 | — | — | US | disclosed |
| US-20210301346-A1 | SEROTONIN TRANSPORTER GENE AND TREATMENT OF OPIOID-RELATED DISORDERS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2021-09-30 | — | — | US | disclosed |
| US-20210290771-A1 | ENGINEERED RECEPTOR/LIGAND SYSTEM FOR DELIVERY OF THERAPEUTIC AGENTS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2021-09-23 | — | — | US | disclosed |
| WO-1999030690-A1 | ORAL DELIVERY FORMULATION | AXIA THERAPEUTICS, INC. (US) | 1999-06-24 | — | — | WO | disclosed |
| WO-1999026661-A1 | A COVALENT CONJUGATE OF CLOZAPINE WITH A FATTY ACID AND ITS USE FOR TREATING SCHIZOPHRENIA | PROTARGA INC. (US) | 1999-06-03 | — | — | WO | disclosed |
| US-5795909-A | ANTICARCINOGENIC AND ANTITUMOR AGENTS; BREAST, COLON, OVARIANCANCERS | NEUROMEDICA, INC. (US) | 1998-08-18 | — | — | US | disclosed |
| US-5780051-A | Methods and articles of manufacture for nicotine cessation and monitoring nicotine use | DYNAGEN, INC. (US) | 1998-07-14 | — | — | US | disclosed |
| EP-0180364-B1 | PHARMACEUTICAL COMPOSITIONS CONTAINING PHENOTHIAZINES | RECKITT AND COLMAN PRODUCTS LIMITED (GB) | 1990-03-07 | — | — | EP | disclosed |
| US-4717723-A | PHENOTHIAZINE DERIVATIVE TO CONTROL NAUSEA, VOMITING, VERTIGO | RECKITT & COLMAN PRODUCTS LIMITED (GB) | 1988-01-05 | — | — | US | disclosed |
| EP-0180364-A2 | Pharmaceutical compositions containing phenothiazines | RECKITT AND COLMAN PRODUCTS LIMITED (GB) | 1986-05-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11905562-B2 | Serotonin transporter gene and treatment of opioid-related disorders | SLC6A4, SLC6A3, SLC6A2 | HRH1 2879/4885HTR1A 16/4885DRD2 23/4885 |
| US-20240247313-A1 | SEROTONIN TRANSPORTER GENE AND TREATMENT OF OPIOID-RELATED DISORDERS | SLC6A4, SLC6A3, SLC6A2 | HRH1 2879/4885HTR1A 16/4885DRD2 23/4885 |
| US-11739063-B2 | DREADD actuators | GRK1, GRK3, GRK2 | HRH1 277/4885HTR1A 169/4885DRD2 373/4885 |
| US-20210301346-A1 | SEROTONIN TRANSPORTER GENE AND TREATMENT OF OPIOID-RELATED DISORDERS | SLC6A4, SLC6A3, SLC6A2 | HRH1 2879/4885HTR1A 16/4885DRD2 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.